Open AccessThromboembolic risks in patients with COVID-19: major concern to consider in our management
Author(s) -
Mazou Ngou Temgoua,
Liliane Mfeukeu Kuaté,
William Ngatchou,
Aurélie T. Sibetcheu,
Zouliatou Nzina Toupendi,
Grace Belobo,
Alice Ossa,
Samuel Kingué
Publication year - 2020
Publication title -
the pan african medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.287
H-Index - 30
ISSN - 1937-8688
DOI - 10.11604/pamj.2020.35.2.22945
Subject(s) - medicine , covid-19 , pandemic , intensive care medicine , incidence (geometry) , clinical trial , risk factor , disease , outbreak , pathology , infectious disease (medical specialty) , physics , optics
COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.